A Phase III, Randomized, Controlled Noninferiority Trial to Study the Efficacy and Safety of Imipenem/cilastatin/relebactam (IMI/REL) Vs Piperacillin/tazobactam (PIP/TAZ) in Patients with Hospital-Acquired Bacterial Pneumonia (HABP) or Ventilator-Associated Bacterial Pneumonia (VABP)

Junjie Li, Feng Wei,Peng Xiang, Zhengang Tang, Lianshu Ding, Luke Francis Chen, Maria Losada, Zlatka Iamboliyska,Fang Sun, Mingfen Zhu, Xiaodan Guo, Xiaoling Du, Chang Chen,Christopher Bruno, Sandra Koseoglu,Katherine Young,Min Zhou,Jieming Qu

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES（2025）

Cited 0|Views5

Key words

Gram-negative bacteria,Multidrug resistance,Nosocomial infection,Pneumonia

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined